Bernstein Starts Biogen (BIIB) at Outperform

Bernstein initiated coverage on Biogen (NASDAQ: BIIB) with an Outperform rating and a price target of $282.00.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $224.60 yesterday.

You May Also Be Interested In

• Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
• Morgan Stanley Assumes Harley-Davidson (HOG) at Overweight, 'Freshly Tuned Up with Open Road Ahead'
• Wells Fargo Starts Americold Realty Trust (COLD) at Equal Weight